Veracyte (NASDAQ:VCYT) released its earnings data on Tuesday. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by $0.04, American Banking & Market News reports. Veracyte Inc (NASDAQ:VCYT) shares after opening at $19 moved to $19 on last trade day and at the end of the day closed at $18.44. Company price to sales ratio in past twelve months was calculated as 19.57 and price to cash ratio as 24.77. Veracyte Inc (NASDAQ:VCYT) showed a positive weekly performance of 6.53%.
Receptos Inc (NASDAQ:RCPT) reported its Q4 2013 and full-year 2013 (period ended December 31, 2013) financial results. For the quarter, the Company reported net loss of $15.2 million, or $0.86 per common share, compared to a net loss of $4.5 million, or $3.08 per common share, in Q4 2012. Total revenues were $773,000, compared to $3.8 million in Q4 2012. Revenue during these periods consisted primarily of amortization of up-front fees and milestone payments, and development funding received from our collaborative arrangements. Receptos Inc (NASDAQ:RCPT) shares fell -1.82% in last trading session and ended the day on $52.80. RPCT return on equity ratio is recorded as -138.90% and its return on assets is -75.50%.
The U.S. Food and Drug Administration approved a drug from Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to treat non-24-hour sleep-wake disorder (or simply ‘non-24’) in January. Hetlioz (tasimelteon) is the first ever drug approved to treat non-24. Non-24 is a chronic circadian rhythm disorder that affects some people who are totally congenitally blind or have lost their vision entirely. Hetlioz is likely to become commercially available in the second quarter of 2014. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares moved down-0.96% in last trading session and was closed at $18.49, while trading in range of $18.10 – 19.00 .Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) year to date (YTD) performance is 48.99%.
IGI Laboratories, Inc. (NYSEMKT:IG), New Jersey based firm reported that it has been notified by the U.S Food and Drug Administration that its new drug application for an updated product of currently in vogue for “lidocaine hydrochloride USP 4%” has been accepted. This was the first abbreviated drug application which has gone through the scanner of FDA and come back approved. The abbreviated drug solution would be used to induce anaesthetic effect in the mouth and nasal cavities. IGI Laboratories, Inc. (NYSEMKT:IG) weekly performance is 21.66%. On last trading day company shares ended up $5.73. IGI Laboratories, Inc. (NYSEMKT:IG) distance from 50-day simple moving average (SMA50) is 49.70%. Analysts mean target price for the company is $5.25.
Leave a Reply